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SDC 1 
HIV-negative study participants 
We estimated median reference ranges for CD4 and CD8 cell count, and the CD4:CD8 ratio using data 
obtained from two sources. One consisted of healthy individuals from the background population to the 
Danish HIV cohort recruited from healthy staff and blood and stem-cell donors. Secondly, we included 
HIV-negative participants from the AGEhIV cohort study, recruited either at the STI clinic of the 
Amsterdam Public Health Service or the existing Amsterdam Cohort Studies on HIV/AIDS [26]. Each 
individual contributed one CD4 and CD8 cell count measurement.  
 
Linear regression was used to obtain reference values for CD4 cell counts, CD8 cell counts and the 
CD4:CD8 ratio according to age and gender. Using the boxcox function in the R package MASS, residuals 
in the linear regression analysis of CD4 cell counts were found to best comply with normality 
assumptions when counts were 5th root transformed, whilst CD8 cell counts and the CD4:CD8 ratio were 
log transformed. The age variable was modeled linearly as well as via restricted cubic splines with 
varying (3-5) number of knots. Differences between models were assessed using the Akaike Information 
Criterion (AIC). We tested for differences between cohorts by including cohort as a covariate in the 
models. We used the estimated 2.5 and 50 prediction percentiles as lower and median reference values 
in the analyses of immunological restoration after starting ART in HIV infected individuals.  
 
Results 
 
CD4 and CD8 cell count and CD4:CD8 ratio measurements were available for 2,309 HIV-negative 
individuals, 1,797 Danish blood and stem cell donors and healthy staff, and 512 participants in the 
AGEhIV cohort study. Supporting information table S1 shows the distribution according to gender and 
age. Participants in the Danish blood donor study were mostly aged between 18 and 45 years whilst all 
of the HIV-negative participants in the AGEhIV study were 45 years of age or older. 
Median CD4 cell count declined with increasing age. The decline in CD4 cell count with increasing age 
was greater in women (p=0.03), than in men (p=0.45). Median CD8 cell count also declined with 
increasing age whilst the median CD4:CD8 ratio increased with increasing age. There was strong 
evidence for a decline in CD8 cell count and an increase in CD4:CD8 ratio with increasing age in both 
men (p=0.0005 and p=0.0008, respectively) and women (both p<0.0001). There was no evidence of a 
difference in CD4 or CD8 cell counts between the two cohorts. There was some evidence that the 
CD4:CD8 ratio in men from the Danish cohort was higher than that in men from the AGEhIV cohort 
(p=0.02).  
  
SDC 2 
HIV-positive study participants 
 
Cohorts included in this paper were AGEhiV the Netherlands, the Cohort of the Spanish HIV Research 
network (CoRIS), Spain; the French Hospital Database on HIV (FHDH); the Italian Cohort of Antiretroviral-
naïve patients (ICONA); the Swiss HIV Cohort Study (SHCS); the AIDS Therapy Evaluation project, 
Netherlands (ATHENA); The Multicenter Study Group on EuroSIDA; the Aquitaine Cohort; the Royal Free 
Hospital Cohort; the South Alberta Clinic Cohort; The Danish HIV Cohort Study, Denmark; HAART 
Observational Medical Evaluation and Research (HOMER) Cohort, Canada; HIV Atlanta Veterans Affairs 
Cohort Study (HAVACS), US; Koln/Bonn Cohort, Germany; Osterreichische HIV-Kohortenstudie 
(OEHIVKOS), Austria; Proyecto para la Informatizacion del Seguimiento Clinico-epidemiologico de la 
Infeccion por HIV y SIDA (PISCIS), Spain; University of Alabama 1917 Clinic Cohort, USA; University of 
Washington HIV Cohort, US; VACH, Spain; Veterans Aging Cohort Study (VACS), US; and Vanderbilt-
Meherry, US. 
  
SDC 3 
Statistical analysis 
 
While ethnicity was known in 40% of individuals, region of birth was known in 84% of individuals and 
was therefore included in the analyses. In individuals with missing region of birth, information on 
ethnicity could be used to reclassify 353 individuals as having been born in Caribbean/South America, 
and 313 as having been born in Sub Saharan Africa. In addition, 4,584 individuals with white ethnicity 
were reclassified as having been born in Europe/North America and 988 with black ethnicity as having 
been born in Sub Saharan Africa (their CD4 cell count trajectories were similar to those born in Sub 
Saharan Africa). The remaining 3,445 individuals were classified into other/unknown region of birth. 
 
Interaction and spline modeling 
The association between continuous covariates and the trajectories of CD4 and CD8 cell counts and their 
ratio were modeled via splines, with knots approximately at the 2.5th, 27.5th, 50th, 72.5th and 97.5th 
percentiles (knots for CD4 cell count at the start were chosen at 10, 160, 260, 375 and 740 cells/mm3, 
knots for CD8 cell count at the start at 190, 560, 830, 1200 and 1600 cells/mm3 and knots for age at the 
start of ART at 22, 32, 39, 47 and 63 years). Log10 transformed plasma viral load was included linearly. 
Furthermore, we allowed the effect of region of birth on the time trend to differ by gender, and we 
allowed for three-way interactions between the time trend and i) age and CD4 cell count at the start of 
ART, ii) gender and age, and iii) gender and CD4 cell count at the start of ART. In these three-way 
interaction terms, time was modeled as a restricted cubic spline with knots at 0, 0.1, 0.25, 3, and 7.5 
years, age at the start of ART as a restricted cubic spline with knots at 22, 39, and 63 years, and CD4 cell 
count at the start of ART as a restricted cubic spline with knots at 10, 260, and 740 cells/mm3. 
Figure SDC4A-C:  Median (solid line), and 25th and 75th percentile (dashed lines) of A: CD4 and B: CD8 cell 
count and C: CD4:CD8 ratio in 1253 HIV-negative men (blue lines) and 1056 women (red lines). 
Individual observations are shown in blue dots for men and red dots for women. 
 
  
Figure SDC5A-C: Median CD4 cell counts (solid lines) and 95% confidence intervals (dashed lines) in HIV-
negative men (dark blue) and women (dark red) obtained using linear regression models with age 
included as restricted cubic spline with 3 (A), 4 (B), and 5 (C) knots. In each figure we also show the 
estimates obtained using models that include age linearly on the transformed scale (blue lines for men 
and red lines for women). The model with 3 knots fitted the data significantly better than the linear 
(p=0.008), the model with 4 knots better than the 3-knot model (p=0.001) and the 5-knot model better 
than the-4 knot model (p=0.004). 
 
3 knots (at 23, 39, and 62 years)    4 knots (at 23, 31,47 and 62 years).  
 
 
Figure SDC6A-C: Median CD8 cell counts (solid lines) and 95% confidence intervals (dashed lines) in HIV-
negative men (dark blue) and women (dark red) obtained using linear regression models with age 
included as restricted cubic spline with 3 (A), 4 (B), and 5 (C) knots. In each figure estimates were 
obtained using models with age included as a linear predictor on the transformed scale are also shown 
(blue lines for men and red lines for women). The fit of the linear model was not significantly different 
from the 3 and 4 knot models and was slightly better for the 5 knot model compared to the linear model 
(p=0.03). 
 
3 knots (at 23, 39, and 62 years)    4 knots (at 23, 31, 47 and 62 years).  
 
5 knots (at 23, 35, 50, 55, and 62 years) 
Figure SDC7A-C: Median CD4:CD8 ratio (solid lines) and 95% confidence intervals (dashed lines) in HIV-
negative men (dark blue) and women (dark red) obtained using linear regression models with age 
included as a restricted cubic spline with 3 (A), 4 (B), and 5 (C) knots. In each figure estimates obtained 
using models including age as a linear predictor on the transformed scale are also shown (blue lines for 
men and red lines for women). The fit of the linear model was not significantly different from the 3 and 
4 knot models and was slightly better for the 5 knot model compared to the linear model (p=0.02).  
 
 
3 knots (at 23, 39, and 62)    4 knots (at 23, 31,47 and 62). 
 
5 knots (at 23, 35, 50, 55, and 62) 
Figure SDC8. Median CD4 count trajectories (95% confidence intervals in colour) during virologically 
suppressive ART according to age at the start of ART, gender, and baseline CD4 cell count at the start. 
Trajectories shown are those for an average individual (in the heterosexual transmission risk group, born 
in Western Europe/North America , starting ART between 2004 and 2006 with a baseline plasma viral 
load of 4.81 log10 copies/ml and with a random intercept and slopes equal to zero). Dashed lines show 
the estimated lower and median reference CD4 cell count. 
  
  
Figure SDC9. Median CD4 cell count at eight years of virologically suppressive ART (95% CI’s in colour) 
according to CD8 cell count at baseline for an average individual (37 year old heterosexual male, born in 
Western Europe/North America with a plasma viral load of 4.81 log10 copies/ml at the start of ART with 
a random intercept and slopes equal to zero). Dashed lines show the lower and median reference CD4 
cell count for a 37-year old male.  
  
Figure SDC10. Median CD8 cell count after eight years of virologically suppressive ART, by CD4 count at 
the start of ART, gender, age eight years after the start, and CD8 cell count at the start of ART for an 
average individual (born in Western-Europe or North-America, in the heterosexual transmission risk 
group and starting ART with HIV RNA 4.81 log10 copies/ml and with a random intercept and slopes equal 
to zero). Dashed lines show the lower, median and upper reference CD8 cell count for various ages.
 
 
  
Figure SDC11. Median CD8 cell count trajectories during eight years of virologically suppressive ART by 
CD4 and CD8 cell count and age at the start of ART for an average reference individual (male 
heterosexual starting ART with a plasma viral load of 4.81 log10 copies/ml, born in Western Europe or 
North America and random intercept and slopes equal to zero). Shaded coloured areas are 95% 
confidence intervals. Dashed lines show the upper, normal and lower reference CD8 cell counts for HIV-
negative subjects of the same gender and age.  
 
 
Figure SDC12. Median CD4:CD8 ratio trajectories (95% confidence intervals in colour) during 
virologically suppressive ART according to gender, and CD4 (vertical axis) and CD8 (upper horizontal axis) 
cell count at the start of ART. Trajectories shown are those for an average reference individual in 
heterosexual transmission risk group, born in Europe/North America, 37 years of age at the start of ART, 
and a plasma viral load of 4.81 log10 copies/ml at the start of ART and random intercept and slopes equal 
to zero. Dashed lines show the lower and normal reference CD4:CD8 ratio.  
 
Supplemental Digital Content 13A-F show the effect of other variables on CD4 cell count response. 
Increases in CD4 cell count during eight years of virologically suppressive ART were smaller in those 
infected through IDU (p<0.0001 compared to non-IDU), in individuals born in Sub Saharan Africa 
(interaction time and region of birth overall p<0.0001), in individuals with lower plasma viral load at the 
start of ART (p<0.0001) in non-smokers (p<0.0001), and in HCV-positive individuals (p<0.0001). Data on 
ribavirin treatment was available for 13 of the 14 cohorts included in the HCV analysis. Ribavirin 
treatment was given for some period during the first eight years of ART to 754 individuals out of 4733 
HCV-positive individuals (16%) from these 13 cohorts. CD4 cell count trajectories were similar in CMV-
negative and positive individuals, although the p-value for the difference in trajectory was 0.0002. CD4 
cell count trajectories according to start year of ART were similar (results not shown).  
 
Figure SDC13A-F. Median CD4 cell count trajectories during virologically suppressive ART (95% 
confidence intervals in colour) according to A) transmission risk group, B) region of birth, C) plasma viral 
load at the start of ART, D) smoking status, E) HCV, and F) CMV co-infection, for an average individual 
(37-year old male, and unless otherwise stated in the legend, not infected through IDU, born in Western 
Europe/North America, starting ART with a HIV RNA of 4.81 copies/ml and a CD4 count of 350 cells/mm3 
and with a random intercept and slopes equal to zero). Dashed lines show the lower and median 
reference CD4 cell count.  
IDU: intravenous drug use, SSA: Sub Saharan Africa, CAR/SA: the Caribbean/South America, EUR/NA: 
Western Europe/North America, HCV: hepatitis C virus, CMV: cytomegalovirus 
 

   
 Supplemental Digital Content 14A-F show that median CD8 cell trajectories were higher in MSM than in 
those in the IDU and heterosexual risk groups (overall p-value for interaction between time and 
transmission risk group p<0.0001). Individuals born in Sub-Saharan Africa showed lower CD8 cell count 
trajectories compared to those born elsewhere (overall p-value for region of birth <0.0001). CD8 cell 
count trajectories were higher when HIV RNA at the start of ART was higher (p<0.0001). CMV-negative 
individuals showed a stronger decrease in CD8 cell count in the first year after starting ART compared to 
CMV-positive individuals (p<0.0001). HCV-negative and positive individuals showed largely similar 
trajectories, although statistically significantly different (p<0.0001). Median CD8 cell count trajectories 
were higher in smokers than in non-smokers (p<0.0001). 
Figure SDC14A-F. Median CD8 cell count trajectories during eight years of virologically suppressive ART 
for an average individual (37-year old male, and unless otherwise stated in the legend, in the 
heterosexual transmission risk group, born in Western Europe/North America, starting ART with a HIV 
RNA of 4.81 copies/ml, a CD4 count of 350 cells/mm3 and a CD8 count of 800 cells/mm3 and with a 
random intercept and slopes equal to zero) according to transmission risk group (A), region of birth (B), 
HIV RNA (C), smoking status (D), HCV status (E), and CMV status (F). Shaded coloured areas are 95% 
confidence intervals. Dashed lines show the lower, median and upper reference CD8 cell counts. 
IDU: intravenous drug use, SSA: Sub Saharan Africa, CAR/SA: the Caribbean/South America, EUR/NA: 
Western Europe/North America, HCV: hepatitis C virus, CMV: cytomegalovirus. 
 
 

  
  
Supplemental Digital Content 15 shows that median CD4:CD8 ratio trajectories were somewhat lower in 
men from Sub Sahara Africa compared to men from Western Europe/North America and the 
Caribbean/South America (interaction between time and region of birth p<0.0001). Furthermore, 
supporting information figure 10A, C, D, E, and F shows that ratios were lower in individuals in the IDU 
transmission risk group compared to those in other risk groups (interaction between time and 
transmission risk group, p<0.0001), in individuals with HCV co-infection at the start of ART (p<0.0001), in 
individuals with a CMV co-infection at the start of ART (p<0.0001), and in those with lower plasma viral 
load at the start of ART (p<0.0001). CD4:CD8 trajectories were similar for smokers and non-smokers 
(p=0.26).  
 
Figure SDC15A-F. Median CD4:CD8 ratio trajectories (95% confidence intervals in colour) during 
virologically suppressive ART according to transmission risk group (A), region of birth (B), HIV RNA (C), 
smoking status (D), HCV co-infection (E), and CMV co-infection (F) at the start of ART. Trajectories are 
shown for an average individual (37-year old male, and unless otherwise stated in the legend, in the 
heterosexual transmission risk group, born in Western Europe/North America, starting ART with a HIV 
RNA of 4.81 copies/ml, a CD4 count of 350 cells/mm3 and a CD8 count of 800 cells/mm3 and with a 
random intercept and slopes equal to zero). Dashed lines show the estimated median and lower 
reference CD4:CD8 ratio. 
IDU: intravenous drug use, SSA: Sub Saharan Africa, CAR/SA: the Caribbean/South America, EUR/NA: 
Western Europe/North America, HCV: hepatitis C virus, CMV: cytomegalovirus. 
 
  
 
Table SDC16. Estimated median (95% CI) CD4 and CD8 cell count (cells/mm3) and the CD4:CD8 ratio at 8 years of virologically suppressive ART 
for an average individual (37-year old male in the heterosexual transmission risk group, born in Western Europe/North America, a CD4 count of 
350 or 500 cells/mm3 and a CD8 count of 800 cells/mm3 and HIV RNA of 4.81 copies/ml at the start and with a random intercept and slopes 
equal to zero). The results of CMV, HCV and smoking status at the start of ART were obtained in the subgroup of cohorts with data available.   
 Baseline CD4 count: 350 cells/mm3 Baseline CD4 count: 500 cells/mm3 
 CD4 cell count CD8 cell count Ratio CD4:CD8 CD4 cell count CD8 cell count Ratio CD4:CD8 
Region of origin       
Europe/North America 784 (770, 797) 649 (621, 678) 1.18 (1.14, 1.22) 910 (892, 928) 637 (603, 674) 1.41 (1.35, 1.48) 
Caribbean/South America 791 (764, 818) 636 (595, 680) 1.20 (1.13, 1.26) 918 (870, 967) 625 (579, 674) 1.44 (1.36, 1.52) 
Sub Saharan Africa 705 (683, 727) 587 (555, 623) 1.18 (1.12, 1.23) 825 (740, 915) 577 (539, 617) 1.42 (1.34, 1.49) 
Other 752 (731, 773) 648 (612, 685) 1.15 (1.10, 1.20) 876 (859, 894) 636 (596, 679) 1.38 (1.31, 1.46) 
Transmission risk group       
IDU 727 (706, 748) 671 (632, 713) 1.02 (0.97, 1.07) 849 (822, 876) 660 (616, 708) 1.23 (1.17, 1.30) 
MSM 787 (772, 802) 658 (633, 683) 1.16 (1.12, 1.19) 914 (892, 936) 647 (614, 680) 1.39 (1.34, 1.45) 
Heterosexual 783 (766, 801) 649 (621, 678) 1.18 (1.14, 1.22) 909 (885, 934) 637 (603, 674) 1.48 (1.38, 1.57) 
Other 765 (744, 785) 630 (592, 672) 1.16 (1.12, 1.21) 890 (863, 917) 619 (576, 666) 1.40 (1.33, 1.47) 
HIV RNA (log10 copies/ml) at 
the start of ART 
      
4.16 747 (733, 762) 643 (615, 672) 1.12 (1.08, 1.16) 871 (850, 893) 632 (597, 668) 1.35 (1.29, 1.40) 
4.81 784 (770, 799) 649 (621, 678) 1.18 (1.14, 1.22) 911 (889, 933) 637 (603, 674) 1.41 (1.35, 1.48) 
5.18 811 (795, 826) 659 (630, 689) 1.22 (1.18, 1.26) 939 (917, 962) 647 (612, 684) 
 
1.46 (1.40, 1.53) 
CMV status at the start of ART       
CMV- 735 (695, 776) 496 (450, 546) 1.42 (1.32, 1.53) 819 (763, 876) 476 (421, 538) 1.64 (1.49, 1.79) 
CMV+ 719 (691, 748) 607 (558, 659) 1.16 (1.09, 1.24) 802 (755, 850) 583 (521, 651) 1.35 (1.24, 1.47) 
Smoking status        
Non-smoker 733 (712, 755) 608 (565, 654) 1.13 (1.07, 1.18) 858 (823, 893) 596 (543, 654) 1.33 (1.24, 1.41) 
Smoker 799 (776, 822) 677 (629, 728) 1.10 (1.05, 1.16) 928 (892, 965) 663 (605, 727) 1.30 (1.22, 1.38) 
HCV status at the start of ART       
HCV- 779 (758, 799) 646 (619, 673) 1.06 (0.98, 1.15) 905 (871, 939) 634 (601, 669) 1.27 (1.15, 1.40) 
HCV+ 736 (702, 770) 658 (622, 697) 0.99 (0.93, 1.05) 858 (815, 903) 646 (605, 691) 1.18 (1.08, 1.29) 
IDU: intravenous drug use, MSM: men having sex with men, HCV: hepatitis C virus, CMV: cytomegalovirus 
 
 
 
